Journal of Hematology & Thromboembolic Diseases
Open Access

Abstract

Serum Soluble CD25 and CD30 Levels as a Biomarker in Adult T-Cell Leukemia/Lymphoma Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Shigeki Takemoto

Adult T-cell leukemia/lymphoma (ATL) is one of the incurable mature T-cell malignancies. Recently, younger survivors after chemotherapy are candidates for allogeneic hematopoietic stem cell transplantation (HSCT). We compared the clinical value of soluble CD30 (sCD30) levels with soluble interleukin 2 receptor α chain (sCD25) levels in 24 ATL patients underwent HSCT at National Hospital Organization Kumamoto Medical Center. In univariate analysis of prognostic factor in patients underwent HSCT, both sCD25 (p=0.041) and sCD30 levels (p=0.0003) levels were significant predictor of overall survival in HSCT. Furthermore, sCD30 levels before the conditioning therapy turns out to predict more patients with early death (7 of 11) than were predicted by sCD25 levels (4 of 11). In addition, regarding graft-versus-host disease (GVHD), no acute GVHD or severe acute GVHD (grade III or IV) (n=10) was associated with unfavorable prognosis in contrast to the favorable prognosis associated with grade I and II (n=14) (hazard ratios=8.2, 95% confidence intervals 2.4–28, p=0.0007). It is thought that sCD30 is a useful biomarker to predict the risks involved with HSCT.